PIK3CA and breast carcinoma: Therascreen PIK3CA RGQ PCR kit has also been approved by the FDA as a companion diagnostic for the detection of PIK3CA mutations in plasma samples from patients with advanced-stage breast cancer to determine their eligibility for blocking the PI3Kα mediated pathway [37].